Treatment for paraganglioma with stereotactic radiotherapy

Table 4 Characteristics of the analyzed studies

Ref.	PGs Resectable	Embolization	Median dose (Gy)	Isodose (%)	Median fractions	Technique	Median volume (mL)/ size (cm)	Outcome
Fatima et al[45]	Yes (NA)	Yes (NA)	15	NA	1-5	CK-GKS-LINAC	8.4 mL	94.2% LC
Patel et al[47]	Yes (10/26)	Yes (1/26)	16	NA	1	GKS	7090 mL	NA
Ehret et al[48]	Yes (20/53)	Yes (8/53)	16.5	70	1	CK	4.3 mL	100% 5-year LC
Marchetti et al[31]	Yes (NA)	No	12.6	78.6	1	CK	3.6 mL	33% LC (35 months)
			25	80	5		16.1 mL
Tosun et al[49]	Yes (NA)	No	24	75	3	CK	35.5 mL	100% LC
Lieberson et al[50]	24/12		20	80	1-5	CK	4.64 mL	100% LC
Dupin et al[51]	Yes (21/81) No (60/21)	Yes (1/81)	25	\	25	60Co machine/ LINAC	30 mL	100% 5-year LC; 98.7% 10-year LC
Main et al[30]	Yes (1/1)	Yes (1/1)	\	\	\	\	93.553 mL	NA
López-Arcas et al[52]	Yes (1/1)	Yes (1/1)	14		2	CK	4 cm	NA
This study	No	No	21	75.5	4	CK	13 mL	100%

PG: Paragangliomas; NA: Not available; CK: Cyberknife System; GKS: Gamma Knife System; LINAC: Linear accelerator; LC: Local control.